IR@PKUHSC  > 北京大学第一临床医学院  > 心血管内科
学科主题临床医学
World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI
Levine, Glenn N.1,2; Jeong, Young-Hoon3,4; Goto, Shinya5; Anderson, Jeffrey L.6; Huo, Yong7; Mega, Jessica L.8; Taubert, Kathryn9; Smith, Sidney C., Jr.10
刊名NATURE REVIEWS CARDIOLOGY
2014-10-01
DOI10.1038/nrcardio.2014.104
11期:10页:597-606
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cardiac & Cardiovascular Systems
资助者Accumetrics ; Boehringer-Ingelheim ; Han-mi Pharmaceuticals ; Haemonetics ; Otsuka ; AstraZeneca ; Bayer ; MSD ; Pfizer/BMS ; Sanofi-Aventis (France) ; Bayer Healthcare ; Bristol-Myers Squibb ; Daiichi Sankyo ; Eli Lilly ; Johnson Johnson ; Nanosphere ; Sanofi-Aventis ; Accumetrics ; Boehringer-Ingelheim ; Han-mi Pharmaceuticals ; Haemonetics ; Otsuka ; AstraZeneca ; Bayer ; MSD ; Pfizer/BMS ; Sanofi-Aventis (France) ; Bayer Healthcare ; Bristol-Myers Squibb ; Daiichi Sankyo ; Eli Lilly ; Johnson Johnson ; Nanosphere ; Sanofi-Aventis
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]PERCUTANEOUS CORONARY INTERVENTION ; ELEVATION MYOCARDIAL-INFARCTION ; ASSOCIATION TASK-FORCE ; TREATMENT PLATELET REACTIVITY ; ELUTING STENT IMPLANTATION ; ACCF/AHA FOCUSED UPDATE ; VERIFYNOW P2Y12 ASSAY ; ST-SEGMENT ELEVATION ; OUTCOMES PLATO TRIAL ; BARE-METAL STENTS
英文摘要

Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention (PCI) have been formulated by both the ACC/AHA and the ESC. These recommendations are based primarily on large, phase III, randomized, controlled trials of the P2Y(12) inhibitors clopidogrel, prasugrel, and ticagrelor. However, few East Asian patients have been included in the trials to assess the use of these agents, particularly the newer agents prasugrel and ticagrelor. Additionally, an increasing body of data suggests that East Asian patients have differing risk profiles for both thrombophilia and bleeding compared with white patients, and that a different ′therapeutic window′ of on-treatment platelet reactivity might be appropriate in East Asian patients. Furthermore, a phenomenon referred to as the ′East Asian paradox′ has been described, in which East Asian patients have a similar or even a lower rate of ischaemic events after PCI compared with white patients, despite a higher level of platelet reactivity during DAPT. Recognizing these concerns, the World Heart Federation has undertaken this evidence-based review and produced this expert consensus statement to determine the antiplatelet treatment strategies that are most appropriate for East Asian patients.

语种英语
资助者Accumetrics ; Boehringer-Ingelheim ; Han-mi Pharmaceuticals ; Haemonetics ; Otsuka ; AstraZeneca ; Bayer ; MSD ; Pfizer/BMS ; Sanofi-Aventis (France) ; Bayer Healthcare ; Bristol-Myers Squibb ; Daiichi Sankyo ; Eli Lilly ; Johnson Johnson ; Nanosphere ; Sanofi-Aventis ; Accumetrics ; Boehringer-Ingelheim ; Han-mi Pharmaceuticals ; Haemonetics ; Otsuka ; AstraZeneca ; Bayer ; MSD ; Pfizer/BMS ; Sanofi-Aventis (France) ; Bayer Healthcare ; Bristol-Myers Squibb ; Daiichi Sankyo ; Eli Lilly ; Johnson Johnson ; Nanosphere ; Sanofi-Aventis
WOS记录号WOS:000342568100007
引用统计
被引频次:50[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63783
专题北京大学第一临床医学院_心血管内科
作者单位1.Baylor Coll Med, Houston, TX 77030 USA
2.Michael E DeBakey VA Med Ctr, Houston, TX USA
3.Gyeongsang Natl Univ Hosp, Jinju, South Korea
4.Gyeongsang Natl Univ, Sch Med, Jinju, South Korea
5.Peking Univ, Hosp 1, Dept Cardiol, Beijing, Peoples R China
6.World Heart Federat, Geneva, Switzerland
7.Tokai Univ, Sch Med, Dept Med Cardiol, Hiratsuka, Kanagawa 25912, Japan
8.Univ Utah, Intermt Med Ctr, Sch Med, Salt Lake City, UT 84112 USA
9.Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA
10.Univ N Carolina, Div Cardiol, Chapel Hill, NC 27599 USA
推荐引用方式
GB/T 7714
Levine, Glenn N.,Jeong, Young-Hoon,Goto, Shinya,et al. World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI[J]. NATURE REVIEWS CARDIOLOGY,2014,11(10):597-606.
APA Levine, Glenn N..,Jeong, Young-Hoon.,Goto, Shinya.,Anderson, Jeffrey L..,Huo, Yong.,...&Smith, Sidney C., Jr..(2014).World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.NATURE REVIEWS CARDIOLOGY,11(10),597-606.
MLA Levine, Glenn N.,et al."World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI".NATURE REVIEWS CARDIOLOGY 11.10(2014):597-606.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Levine, Glenn N.]的文章
[Jeong, Young-Hoon]的文章
[Goto, Shinya]的文章
百度学术
百度学术中相似的文章
[Levine, Glenn N.]的文章
[Jeong, Young-Hoon]的文章
[Goto, Shinya]的文章
必应学术
必应学术中相似的文章
[Levine, Glenn N.]的文章
[Jeong, Young-Hoon]的文章
[Goto, Shinya]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。